MX9203602A - Administracion iontoforetica mejorada de farmacos. - Google Patents

Administracion iontoforetica mejorada de farmacos.

Info

Publication number
MX9203602A
MX9203602A MX9203602A MX9203602A MX9203602A MX 9203602 A MX9203602 A MX 9203602A MX 9203602 A MX9203602 A MX 9203602A MX 9203602 A MX9203602 A MX 9203602A MX 9203602 A MX9203602 A MX 9203602A
Authority
MX
Mexico
Prior art keywords
improved pharmaceutical
iontophoretic administration
iontophoretic
administration
pharmaceutical
Prior art date
Application number
MX9203602A
Other languages
English (en)
Inventor
Robert S Hillmen
John M Pawelchak
Original Assignee
Gensia Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gensia Pharma filed Critical Gensia Pharma
Publication of MX9203602A publication Critical patent/MX9203602A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
    • A61K31/621—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate having the hydroxy group in position 2 esterified, e.g. benorylate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
MX9203602A 1990-04-12 1992-06-26 Administracion iontoforetica mejorada de farmacos. MX9203602A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50932290A 1990-04-12 1990-04-12
US07/680,577 US5383848A (en) 1990-04-12 1991-04-04 Iontophoretic administration of drugs

Publications (1)

Publication Number Publication Date
MX9203602A true MX9203602A (es) 1992-07-01

Family

ID=27056508

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9203602A MX9203602A (es) 1990-04-12 1992-06-26 Administracion iontoforetica mejorada de farmacos.

Country Status (8)

Country Link
US (1) US5383848A (es)
EP (1) EP0525055A4 (es)
JP (1) JPH06500708A (es)
AU (1) AU7761591A (es)
CA (1) CA2080012A1 (es)
IE (1) IE911249A1 (es)
MX (1) MX9203602A (es)
WO (1) WO1991016103A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5749847A (en) * 1988-01-21 1998-05-12 Massachusetts Institute Of Technology Delivery of nucleotides into organisms by electroporation
CA2114968A1 (en) * 1993-02-25 1994-08-26 John Wille Transdermal treatment with mast cell degranulating agents for drug-induced hypersensitivity
US20020114827A1 (en) * 1995-07-28 2002-08-22 Jie Zhang Methods and apparatus for improved administration of analgesics
US5983131A (en) * 1995-08-11 1999-11-09 Massachusetts Institute Of Technology Apparatus and method for electroporation of tissue
US6852690B1 (en) 1995-08-22 2005-02-08 Amylin Pharmaceuticals, Inc. Method and composition for enhanced parenteral nutrition
DK172203B1 (da) * 1996-03-11 1998-01-05 Gitte Bjeldbak Elskovsmiddel, der virker seksuelt ophidsende på brugeren
US5911223A (en) * 1996-08-09 1999-06-15 Massachusetts Institute Of Technology Introduction of modifying agents into skin by electroporation
US6085115A (en) * 1997-05-22 2000-07-04 Massachusetts Institite Of Technology Biopotential measurement including electroporation of tissue surface
US5954675A (en) * 1997-07-07 1999-09-21 Dellagatta; Enrico Michael Method of ultrasonic therapy
US6835184B1 (en) * 1999-09-24 2004-12-28 Becton, Dickinson And Company Method and device for abrading skin
DE60011670T2 (de) 1999-12-07 2004-10-21 Medrad Inc Spritzen, spritzenschläuche und flüssigkeitsübertragungssysteme
US20030064122A1 (en) * 2001-05-23 2003-04-03 Endo Pharmaceuticals, Inc. Abuse resistant pharmaceutical composition containing capsaicin
TWI220386B (en) * 2002-01-21 2004-08-21 Matsushita Electric Works Ltd Ultrasonic transdermal permeation device
JP2006522815A (ja) * 2003-04-08 2006-10-05 アルゴルクス ファーマスーティカルズ，インク 合成カプサイシンの製造および精製
CA2680675C (en) * 2003-06-13 2012-05-15 The Procter & Gamble Company Sonophoresis skin care device
US8666486B2 (en) 2004-03-04 2014-03-04 Hadasit Medical Research Services & Development Limited Safe device for iontophoretic delivery of drugs
US20060009727A1 (en) * 2004-04-08 2006-01-12 Chf Solutions Inc. Method and apparatus for an extracorporeal control of blood glucose
US20060013866A1 (en) * 2004-07-16 2006-01-19 Carter Stephen G Transdermal drug delivery formulations with optimal amounts of vasodilators therein
US20060013769A1 (en) * 2004-07-16 2006-01-19 Stephen Carter Transdermal drug delivery formulations and method of determining optimal amounts of vasodilators therein
US7704522B2 (en) * 2004-09-08 2010-04-27 Clyde Morgan Topical medicament
EA200701131A1 (ru) * 2004-11-24 2007-12-28 Алгоркс Фармасьютикалз, Инк. Гелеобразная препаративная форма капсаициноида и способы её применения
US8323194B2 (en) * 2009-12-18 2012-12-04 Inlight Solutions, Inc. Detection of bubbles during hemodynamic monitoring when performing automated measurement of blood constituents
US20100094114A1 (en) * 2008-10-09 2010-04-15 Mark Ries Robinson Use of multiple calibration solutions with an analyte sensor with use in an automated blood access system
US20090054754A1 (en) * 2007-08-21 2009-02-26 Mcmahon Dave Clinician-controlled semi-automated medication management
US20090156975A1 (en) * 2007-11-30 2009-06-18 Mark Ries Robinson Robust System and Methods for Blood Access
US20090088615A1 (en) * 2007-10-01 2009-04-02 Mark Ries Robinson Indwelling Fiber Optic Probe for Blood Glucose Measurements
US20090048535A1 (en) * 2007-08-13 2009-02-19 Mark Ries Robinson Detecting Cross-contamination in Blood Measurements with a Multilumen Catheter
US20100168535A1 (en) * 2006-04-12 2010-07-01 Mark Ries Robinson Methods and apparatuses related to blood analyte measurement system
EP1954190A4 (en) * 2005-11-15 2010-10-13 Luminous Medical Inc BLUTANALYTBESTIMMUNGEN
US20090054497A1 (en) * 2007-08-21 2009-02-26 Nawaz Ahmad Methods for attaining enhanced sexual wellness using anhydrous compositions
US20090054498A1 (en) * 2007-08-21 2009-02-26 Nawaz Ahmad Anhydrous Compositions Useful for Attaining Enhanced Sexual Wellness
US20090197892A1 (en) * 2007-08-21 2009-08-06 Nawaz Ahmad Anhydrous compositions useful for attaining enhanced sexual wellness
FR2959131B1 (fr) * 2010-04-23 2016-04-01 Francois Forestier Cache-col thermique
BR112015002295B1 (pt) 2012-07-31 2022-02-01 The Board Of Regents Of The University Of Texas System Método para induzir a formação de célula beta in vitro

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4291015A (en) * 1979-08-14 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing a vasodilator
US4615699A (en) * 1985-05-03 1986-10-07 Alza Corporation Transdermal delivery system for delivering nitroglycerin at high transdermal fluxes
BR8507219A (pt) * 1985-06-10 1987-08-04 Drug Delivery Systems Inc Sistema de montagem e controle programavel para aplicador de droga transdermico
US4722726A (en) * 1986-02-12 1988-02-02 Key Pharmaceuticals, Inc. Method and apparatus for iontophoretic drug delivery
IE60941B1 (en) * 1986-07-10 1994-09-07 Elan Transdermal Ltd Transdermal drug delivery device
WO1988008729A1 (en) * 1987-05-15 1988-11-17 Newman Martin H Iontophoresis drug delivery system
US4845233A (en) * 1987-09-11 1989-07-04 Iprx, Inc. Imidazolin-2-ones
US4814168A (en) * 1988-03-04 1989-03-21 Noven Pharmaceuticals, Inc. Transdermal multipolymer drug delivery system
US5088977A (en) * 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
US5002773A (en) * 1989-09-29 1991-03-26 Marion Merrell Dow Inc. Transdermal delivery of (+) (2S,3S)-3-acetoxy-8-chloro-5-(2-dimethylaminoethyl)-2,3-dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepin-4-(5H)-one
US5023085A (en) * 1989-11-29 1991-06-11 Pfizer Inc. Transdermal flux enhancers in combination with iontophoresis in topical administration of pharmaceuticals

Also Published As

Publication number Publication date
EP0525055A1 (en) 1993-02-03
WO1991016103A1 (en) 1991-10-31
EP0525055A4 (en) 1993-10-06
AU7761591A (en) 1991-11-11
CA2080012A1 (en) 1991-10-13
US5383848A (en) 1995-01-24
JPH06500708A (ja) 1994-01-27
IE911249A1 (en) 1991-10-23

Similar Documents

Publication Publication Date Title
MX9203602A (es) Administracion iontoforetica mejorada de farmacos.
FI915826A (fi) Farmaceutiska aemnen.
DE68911473D1 (de) Arzneimittelformulierungen.
FI921060A0 (fi) Farmaceutiska aerosolformuleringar.
FI922958A0 (fi) Farmaceutisk sammansaettning.
FI922252A0 (fi) Farmaceutisk sammansaettning.
FI922316A0 (fi) Farmaceutisk sammansaettning.
DE69113205D1 (de) Transdermales therapeutisches System.
NO912799L (no) Foradditiver for droevtyggere.
DE69018647T2 (de) Arzneimittel.
FI906367A0 (fi) Terapeutiska nukleosider.
FI913899A0 (fi) Terapeutiska aerosolblandningar.
FI923581A0 (fi) Farmaceutisk kombinationsformation.
FI893340A (fi) Foerfarande foer att erhaolla farmaceutiska sammansaettningar foer att hindra smittbara koenssjukdomar.
FI911652A (fi) Farmaceutisk beredning av nitroglycering foer perkutan administration.
NO911429L (no) Stoffbehandling.
FI904854A0 (fi) Terapeutiska nukleosider.
FI905236A0 (fi) Deoxiribonukleosider innehaollande farmaceutiska konsistenser foer laekning av saor.
NO911430L (no) Stoffbehandlingsmetode.
FI923371A0 (fi) En farmaceutisk formulation.
FI923486A0 (fi) Terapeutiska aemnen.
FI875616A (fi) Farmaceutiska blandningar.
FI910753A (fi) Terapeutiska nukleocider.
FI923528A0 (fi) Terapeutiska aemnen.
DE3887237D1 (de) Arzneimittel.